RESUMO
In allogeneic hematopoietic stem cell transplantation (HSCT), granulocyte transfusions (GT) may be required in immunocompromised, neutropenic patients. In this context, alloimmunization against alloantigens may occur and affect HSCT outcome. Anti-human leukocyte antigen (HLA) and -MHC class I chain related antigens A (MICA) antibody response after the administration of GT in 29 patients undergoing allogeneic HSCT (n = 27) encompassing 109 sera was investigated by multianalyte microbead assay before and up to 6 month after HSCT. Anti-HLA class I and II antibodies emerged de novo in 11 (38%) and 4 (14%) patients, respectively. Similarly, preformed antibodies were observed in four cases (14%) for anti-HLA class I and also four patients for anti-HLA class II antibodies. Anti-MICA antibodies were observed in eight granulocyte recipients of which three patients developed anti-MICA antibodies after GT, whereas preformed antibodies were seen in five patients. The conversion to positivity for any of the investigated antibodies did not significantly affect overall survival or the incidence of GVHD. GT-associated alloantibody conversion observed did not significantly correlate with outcome. Thus, surveillance of anti-HLA antibodies in the course of GT in the context of HSCT may not be required routinely. The role of MICA antibodies in HSCT and GT, however, requires further study.
Assuntos
Granulócitos/transplante , Transplante de Células-Tronco Hematopoéticas/métodos , Imunização , Adolescente , Adulto , Idoso , Plaquetas/metabolismo , Criança , Pré-Escolar , Feminino , Fluorescência , Antígenos de Histocompatibilidade Classe I/imunologia , Antígenos de Histocompatibilidade Classe II/imunologia , Humanos , Isoanticorpos/imunologia , Masculino , Pessoa de Meia-Idade , Transplante Homólogo , Resultado do Tratamento , Adulto JovemRESUMO
Acquired hemophilia A is a rare, potentially life-threatening disease resulting from autoantibodies against coagulation factor VIII. We report the case of a patient with acquired hemophilia A and severe bleeding after incision of a peritonsillar abscess. Treatment with high dose factor VIII and recombinant activated factor VII failed to control bleeding. However, a single infusion of recombinant porcine factor VIII stopped bleeding efficiently and resulted in measurable factor VIII levels.
Assuntos
Autoanticorpos , Fator VIII , Hemofilia A , Idoso , Animais , Autoanticorpos/sangue , Autoanticorpos/imunologia , Testes de Coagulação Sanguínea , Fator VIII/imunologia , Hemofilia A/sangue , Hemofilia A/imunologia , Hemorragia , Humanos , Masculino , SuínosAssuntos
Lesão Pulmonar Aguda/induzido quimicamente , Fator Estimulador de Colônias de Granulócitos/efeitos adversos , Mobilização de Células-Tronco Hematopoéticas/efeitos adversos , Doenças Pulmonares Intersticiais/etiologia , Transplante de Células-Tronco de Sangue Periférico , Doadores não Relacionados , Injúria Renal Aguda/induzido quimicamente , Lesão Pulmonar Aguda/etiologia , Adulto , Bronquite/complicações , Enterococcus faecium , Feminino , Infecções por Bactérias Gram-Positivas/complicações , Infecções por Bactérias Gram-Positivas/microbiologia , Fator Estimulador de Colônias de Granulócitos/farmacologia , Humanos , Vírus da Influenza A Subtipo H1N1/isolamento & purificação , Vírus da Influenza B/isolamento & purificação , Influenza Humana/complicações , Influenza Humana/virologia , Lenograstim , Doenças Pulmonares Intersticiais/tratamento farmacológico , Masculino , Otite Média/complicações , Otite Média/microbiologia , Derrame Pleural/etiologia , Pneumonia Viral/complicações , Pneumonia Viral/virologia , Prednisona/uso terapêutico , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/farmacologia , Adulto JovemAssuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/imunologia , Transfusão de Sangue , Política Organizacional , Transplante de Células-Tronco , Quimeras de Transplante/imunologia , Transplante Homólogo/imunologia , Sistema ABO de Grupos Sanguíneos/genética , Anemia Hemolítica/etiologia , Anemia Hemolítica/imunologia , Anemia Hemolítica/prevenção & controle , Sobrevivência de Enxerto , Humanos , Doadores de Tecidos , Reação Transfusional , Condicionamento Pré-TransplanteRESUMO
A patient with CML in accelerated phase received G-CSF-mobilized PBPC from an unrelated HLA genotypically matched donor. The blood groups of the patient and donor were bidirectionally incompatible. Hematologic recovery was rapid with > 500 PMN/microliter on day +9. Starting on day +5 bilirubin levels increased from 1.3 mg/dl up to a maximum of 18 mg/dl on day +14. Clinical signs and laboratory tests supported major hemolysis. Blood typing on day +16 revealed early blood-group change, consistent with donor-derived antibodies produced by passenger-lymphocytes which may have mediated severe hemolysis. The early onset and strong intensity of the hyperbilirubinemia could be a specific feature of ABO-incompatible allogeneic PBPC transplantation which would be difficult to differentiate from GVHD or VOD.
Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Hemólise , Sistema ABO de Grupos Sanguíneos , Adulto , Sobrevivência de Enxerto , Teste de Histocompatibilidade , Humanos , Masculino , Transplante HomólogoRESUMO
Allogeneic peripheral blood stem cell transplantation leads to an earlier engraftment compared to BMT. The feasibility, acceptance and long-term side-effects of G-CSF mobilisation of PBSC in unrelated healthy donors needs to be evaluated. Forty unrelated healthy donors received G-CSF in a dose of 10 microg/kg bodyweight for 5 days and two aphereses were performed. The donors were monitored prospectively. The data were compared to bone marrow harvests from unrelated donors. Almost all stem cell donors reported some side-effects due to Filgrastim application. Bone pain (32), headache (20), chest pain (two) and night sweats (one) were complained of. By taking analgesics, the pain was relieved in most cases. No donor discontinued the filgrastim application. Bone pain and headache resolved within 2-4 days after termination of Filgrastim application. There was, as expected, a seven-fold increase in the number of total WBCs. There were no significant changes of platelet counts during G-CSF application. After 4 weeks haemoglobin concentration and platelet counts showed no significant differences compared to baseline values. The aphereses were mostly tolerated very well. Eighteen donors reported paraesthesia, one donor developed dizziness, two complained of nausea and vomiting. There was a significant decrease in platelet count (242 before, 98 x 10(9)/l after aphereses). Autologous platelets were transfused after the second aphereses in four donors. These data were compared to data from 245 unrelated bone marrow donors, who had on average, 14 days bone pain and tiredness after donation. The G-CSF mobilisation and apheresis of peripheral blood stem cells is an alternative to traditional bone marrow harvesting in unrelated healthy donors. It is well tolerated and the duration of side-effects on average is shorter than after the surgical procedure. So far no long-term effects have been observed in the follow-up.
Assuntos
Doadores de Sangue , Transplante de Medula Óssea , Medula Óssea/patologia , Mobilização de Células-Tronco Hematopoéticas , Transplante de Células-Tronco Hematopoéticas , Doadores de Tecidos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Transplante HomólogoRESUMO
Engraftment was achieved in 43/45 (95%) recipients of peripheral blood stem cells (PBSC) from HLA-compatible unrelated donors (n = 45), compared to all 45 patients in matched controls receiving bone marrow and 14/18 (78%) recipients of CD34-selected PBSC (P < 0.01). The time to reach ANC >0.5 x 10(9)/l was a median of 16 days in the PBSC and CD34 groups, compared to 20 days in the bone marrow controls (P < 0.001 vs PBSC). The time to reach platelets >50 x 10(9)/l was a median of 23 days in the PBSC group and 24 days in the CD34 group, which was significantly faster than 29 days in the bone marrow controls (P < 0.01). Acute GVHD grades II-IV developed in 30% in the PBSC group, 20% in the recipients of bone marrow and 18% in the CD34 group. The corresponding figures for chronic GVHD were 59%, 85% and 0% (P < 0.01) in the three groups, respectively. The probability of non-relapse death was 27% in the recipients of PBSC, 21% in the bone marrow controls and 60% in the CD34 group (NS). The 2-year leukaemia-free survival was 46% in the PBSC group, 41% in the bone marrow group and 25% in the CD34 group (NS).
Assuntos
Plaquetas/patologia , Transplante de Medula Óssea , Transplante de Células-Tronco Hematopoéticas , Neutrófilos/patologia , Adolescente , Adulto , Criança , Pré-Escolar , Intervalo Livre de Doença , Sobrevivência de Enxerto , Antígenos HLA , Humanos , Leucemia/sangue , Leucemia/imunologia , Leucemia/terapia , Pessoa de Meia-Idade , Fatores de Tempo , Transplante HomólogoRESUMO
Sezary syndrome is defined as the leukemic variation of cutaneous T-cell lymphomas. Here we describe the cytogenetic pattern of peripheral T-cells of a 50-year-old male patient suffering from this disease. We used Giemsa-banding (G-banding) technique and a fluorescence in situ hybridization (FISH) assay to determine cytogenetic changes affecting 15 different chromosomes. The cells displayed an abnormal hypodiploid karyotype with a prominent insertion located at the short arm of chromosome 1. Unbalanced translocations were observed involving chromosomes 4 and 14. Besides other abnormalities we detected a 6q- deletion. These multiple genetic changes may reflect the high aggressivity of the neoplastically transformed T-cell population and the poor response to chemotherapeutic treatment.
Assuntos
Linfócitos T CD4-Positivos/patologia , Linfócitos T CD8-Positivos/patologia , Aberrações Cromossômicas , Células-Tronco Neoplásicas/patologia , Síndrome de Sézary/genética , Aneuploidia , Bandeamento Cromossômico , Evolução Fatal , Humanos , Imunofenotipagem , Hibridização in Situ Fluorescente , Masculino , Pessoa de Meia-Idade , Células-Tronco Neoplásicas/imunologia , Síndrome de Sézary/patologiaRESUMO
Therapeutic application of natalizumab, an anti-CD49d Ab, in patients with multiple sclerosis (MS) has been associated with increased levels of circulating CD34+ progenitors. We analyzed the frequency, phenotype and functional activity of CD34+ HSC in blood and BM of patients with MS who were treated with natalizumab. Compared with healthy controls and untreated MS patients, natalizumab treatment increased CD34+ cells in the peripheral blood 7-fold and in BM 10-fold. CD34+ cells derived from blood and marrow of natalizumab-treated patients expressed less of the stem cell marker CD133, were enriched for erythroid progenitors (CFU-E) and expressed lower levels of adhesion molecules than G-CSF-mobilized CD34+ cells. The level of surface CXCR-4 expression on CD34+ cells from patients treated with natalizumab was higher compared with that of CD34+ cells mobilized by G-CSF (median 43.9 vs 15.1%). This was associated with a more than doubled migration capacity toward a chemokine stimulus. Furthermore, CD34+ cells mobilized by natalizumab contained more mRNA for p21 and less for matrix metallopeptidase 9 compared with G-CSF-mobilized hematopoietic stem cell (HSC). Our data indicate that G-CSF and CD49d blockade mobilize different HSC subsets and suggest that both strategies may be differentially applied in specific cell therapy approaches.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Células Precursoras Eritroides/efeitos dos fármacos , Hematopoese/efeitos dos fármacos , Mobilização de Células-Tronco Hematopoéticas , Imunossupressores/uso terapêutico , Integrina alfa4/imunologia , Esclerose Múltipla/tratamento farmacológico , Antígeno AC133 , Adulto , Anticorpos Monoclonais Humanizados , Antígenos CD/metabolismo , Antígenos CD34/sangue , Antígenos CD34/metabolismo , Células da Medula Óssea/metabolismo , Movimento Celular/efeitos dos fármacos , Inibidor de Quinase Dependente de Ciclina p21/genética , Inibidor de Quinase Dependente de Ciclina p21/metabolismo , Células Precursoras Eritroides/fisiologia , Feminino , Glicoproteínas/metabolismo , Células-Tronco Hematopoéticas/efeitos dos fármacos , Células-Tronco Hematopoéticas/fisiologia , Homeostase , Humanos , Imunofenotipagem , Masculino , Metaloproteinase 9 da Matriz/genética , Metaloproteinase 9 da Matriz/metabolismo , Esclerose Múltipla/sangue , Esclerose Múltipla/metabolismo , Natalizumab , Peptídeos/metabolismo , RNA Mensageiro/metabolismoRESUMO
Mesenchymal stem cells have been shown to mediate immunomodulatory effects. They have been used in patients with steroid-refractory acute GVHD (aGVHD), but their relevance as a therapeutic agent targeting aGVHD has still to be defined. In this case series, we report 13 patients with steroid-refractory aGVHD who received BM-derived MSC expanded in platelet lysate-containing medium from unrelated HLA disparate donors. MSC were characterized by their morphological, phenotypical and functional properties. All tested preparations suppressed the proliferation of in vitro activated CD4+ T cells. MSC were transfused at a median dosage of 0.9 x 10(6)/kg (range 0.6-1.1). The median number of MSC applications was 2 (range 1-5). Only two patients (15%) responded and did not require any further escalation of immunosuppressive therapy. Eleven patients received additional salvage immunosuppressive therapy concomitant to further MSC transfusions, and after 28 days, five of them (45%) showed a response. Four patients (31%) are alive after a median follow-up of 257 days, including one patient who initially responded to MSC treatment. In our patient cohort, response to MSC transfusion was lower than in the series reported earlier. However, our experience supports the potential efficacy of MSC in the treatment of steroid-refractory aGVHD.
Assuntos
Plaquetas/fisiologia , Doença Enxerto-Hospedeiro/terapia , Transplante de Células-Tronco Mesenquimais , Células-Tronco Mesenquimais/citologia , Doença Aguda , Adulto , Idoso , Plaquetas/química , Linfócitos T CD4-Positivos/imunologia , Feminino , Doença Enxerto-Hospedeiro/tratamento farmacológico , Doença Enxerto-Hospedeiro/imunologia , Transplante de Células-Tronco Hematopoéticas , Humanos , Imunossupressores/uso terapêutico , Ativação Linfocitária , Masculino , Células-Tronco Mesenquimais/imunologia , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
BACKGROUND: In humans approx. 10% of the total body selenium (Se) content is present in the blood being evenly distributed among plasma and red cells. The important role of Se in antioxidative biological pathways is proven. Many parents of children with malignancies ask for supplementation with Se as part of complementary therapy during or after the oncological treatment. However, toxic Se concentrations may easily be reached in children. In order to analyse whether Se is also supplied by red cell transfusions (RCT), we determined Se concentration in whole blood prior and after packed RCT in pediatric patients with hemato-oncological diseases. PATIENTS AND METHODS: EDTA-blood was collected from 17 patients (median age: 4 years, range: 1 month - 17 years) with aplastic anemia, acute leukemia and solid tumours prior and after RCT (n=60). Patients received a median of 2 transfusions (range: 1-14). Samples were also collected from the transfusion blood bags and Se concentration was determined quantitatively by atomic absorption spectrometry. RESULTS: 95% of the specimen collected from the transfusion bags exhibited selenium concentrations within the normal adult range. Mean Se concentration in the patients' blood prior to RCT was 66.2 microg/l (range: 38.0-166.4 microg/l) and increased to 70.7 microg/l (range: 14.1-105.1 microg/l) thereafter (statistically not significant). Applying age dependant reference values Se concentrations were below the lower limit in 45% of the samples prior to RCT and only in 26% after RCT. The reason for this increase was the fact that Se concentrations were often just marginally below the age-dependant lower limit prior to RCT and in the lower normal range thereafter. CONCLUSION: 43% of the patients with hemato-oncological diseases in this study exhibited no Se deficiency at any time point. In the remaining 57% of the patients a transient or persistent Se deficiency was detected with blood levels partially far below the lower threshold of the age adjusted normal range. The Se deficiency was corrected in four out of eight patients by RCT. As Se levels may fluctuate in individual pts a supplementation should only be initiated if based on regular monitoring of the Se concentration.
Assuntos
Anemia Aplástica/terapia , Transfusão de Eritrócitos , Leucemia/terapia , Neoplasias/terapia , Selênio/sangue , Doença Aguda , Adolescente , Anemia Aplástica/sangue , Criança , Pré-Escolar , Eritrócitos/metabolismo , Feminino , Humanos , Lactente , Leucemia/sangue , Masculino , Neoplasias/sangue , Valores de ReferênciaRESUMO
In a retrospective study 152 children and adolescents were selected from a collective of 3017 patients who participated in a predeposited autologous blood program from 1991 to 1995. 107 patients were female and 45 male. Average age was 14.4 years (range 6-18 years) and the body weights ranged from 27 to 79 kg. 90% underwent orthopedic surgery, 53% for scoliosis. Patients donated altogether 366 transfusion units (TE), an average of 2.4 TE was performed on each patient. Male patients had a higher level of hemoglobin than female and yielded the 4 autologous blood donations 5 days before female patients. Operation and hospitalization were completed by 44% without receiving any homologous blood, and 17% of patients needed only 1 homologous blood donation in addition to autologous blood. Preoperative blood donation led to no significant complications. We conclude that the autologous blood program is an effective and safe means of blood replacement, and is suitable for use in children and adolescents.
Assuntos
Transfusão de Sangue Autóloga/estatística & dados numéricos , Adolescente , Perda Sanguínea Cirúrgica/fisiopatologia , Criança , Feminino , Alemanha , Hemoglobinometria , Humanos , Masculino , Prognóstico , Estudos Retrospectivos , Escoliose/sangue , Escoliose/cirurgiaRESUMO
BACKGROUND: Allogeneic bone marrow and peripheral blood stem cell transplantation is the treatment of choice for a number of malignant hematological diseases, marrow failure syndromes and severe congenital immunodeficiency states. As a new, valuable source of hematopoietic stem cells, cord blood has become increasingly attractive to the medical community. More than 1500 related and unrelated cord blood transplantations have already been performed worldwide. Cord blood can be a particularly good alternative source of stem cells for pediatric patients, if no HLA-identical donor can be found. MATERIAL AND METHODS: In August 1997 the Cord Blood Bank at the University Hospital of Dresden initiated the collection, processing and cryopreservation of placental blood. This Cord Blood bank is promoted by the German bone marrow donor registry DKMS in Tübingen/Germany collaborating with 8 gynecological clinics in Dresden, Bautzen and Erlabrunn. Before cryopreservation, volume reduction of cord blood units is routinely performed by centrifugation and by separation of the buffy coat. RESULTS: As of March 2000, more than 2200 cord blood units have been collected. 60% of the samples had to be discarded because of insufficient quality (low volume and/or cell count, bacterial contamination, positive infectious disease markers). However, more than 800 cord blood units met all quality control criteria and were cryopreserved. CONCLUSION: These data from the Cord Blood Bank at the University Hospital of Dresden are comparable with results from other cord blood banks. Efforts directed toward the cryopreservation and banking of increased numbers of cord blood units are being continued worldwide and should be supported by the general public.
Assuntos
Bancos de Sangue/organização & administração , Medula Óssea , Sangue Fetal , Sistema de Registros , Doadores de Tecidos , Preservação de Sangue , Criopreservação , Feminino , Alemanha , Hospitais Universitários , Humanos , Recém-Nascido , Placenta , GravidezRESUMO
Fifty-one adults with haematological malignancies were transplanted with CD34+-selected peripheral blood progenitor cells (PBPC) from unrelated donors. The conditioning protocol contained total body irradiation (n = 17) or combinations of busulphan and other alkylating agents (n = 34). Antithymocyte globulin was infused in all patients. The median number of CD3+ T cells infused with the graft after purification with the Isolex 300 system in the first cohort of 18 patients was 2.1 x 10(5)/kg. Prophylactic donor lymphocyte infusion (DLI) containing 1 x 10(5) CD3+ T cells was performed on d 21 in the following 33 patients who had received PBPC purified by the CliniMACS system. Early graft failure occurred in 8/51 patients (16%). After a median follow-up of 31 months (range 8-60), the probability of disease-free survival (DFS) was 36% for the whole group. Reasons for death were opportunistic infections (n = 15), graft-versus-host disease (GvHD, n = 7) and relapse (n = 4). Pre-transplant factors with significant impact on DFS were cytomegalovirus status and risk category of underlying disease. The occurrence of graft failure or GvHD was associated with poor outcome. Recipients of CD34+-selected PBPC from unrelated donors are at high risk of infectious complications, relapse and graft failure which cannot be prevented by early reinfusion of unmodified donor lymphocytes.
Assuntos
Antígenos CD34 , Neoplasias Hematológicas/cirurgia , Transplante de Células-Tronco , Linfócitos T , Adolescente , Adulto , Transfusão de Sangue Autóloga , Criança , Infecções por Citomegalovirus , Feminino , Rejeição de Enxerto , Neoplasias Hematológicas/terapia , Humanos , Transfusão de Linfócitos , Masculino , Pessoa de Meia-Idade , Infecções Oportunistas , Análise de Regressão , Reoperação , Transplante HomólogoRESUMO
Allogeneic bone marrow and peripheral blood stem cell transplantation is the treatment of choice for some malignant hematologic diseases, marrow failure syndromes, and severe congenital immunodeficiency states. Since Gluckman et al reported in 1988 the first successful human leukocyte antigen (HLA)-matched sibling umbilical cord blood stem cell transplantation, it has been known that cord blood is a valuable source of hematopoietic stem cells. The Cord Blood Bank at the University Hospital of Dresden was founded in 1997 and started collecting, processing, and cryoconserving umbilical cord blood in August 1997. The cord blood bank is supported by the largest German donor registry: Deutsche Knochenmarkspenderdatei (DKMS) in Tubingen, Germany. With the informed consent of the mothers, the collection is performed in collaboration with six hospitals in Dresden, Berlin, and Bautzen. We routinely perform a volume reduction by centrifuging the blood bag and expressing the leukocyte-rich supernatant. Routinely, sterility, total nucleated cells (TNC), CD34+ cell count, HLA class I and II, ABO/Rh blood group, and colony-forming units are evaluated. The maternal blood is screened for anti-immunodeficiency virus (anti-HIV), anti-hepatitis C virus (anti-HCV), anti-hepatitis B surface antigen (HBsAg), anti-hepatitis B surface (anti-HBs), anti-hepatitis B core (anti-HBc), anticytomegalovirus (anti-CMV), and toxoplasmosis and with Treponema pallidum hemagglutination assay (TPHA). More than 1,000 cord blood units could be collected. Because of the required volume and cell count and because of sterility, 50% of the collected units had to be discharged. Our results are comparable with data of other cord blood banks: mean volume 79 mL; cell count after volume reduction-TNC, 7.16 x 10(8); mononucleated cells (MNC), 3.75 x 10(8); CD34+ cells, 1.95 x 10(6); colony-forming units (CFU), 67.1 x 10(4). To increase the pool of potential umbilical cord blood units and in order to evaluate the possibility for unrelated transplants, cryopreservation and banking of large numbers of cord bloods are necessary.
Assuntos
Armazenamento de Sangue/métodos , Animais , Bancos de Sangue/estatística & dados numéricos , Sangue Fetal/citologia , Alemanha , Humanos , Sistema de Registros , Células-TroncoRESUMO
BACKGROUND AND OBJECTIVES: Allogeneic peripheral blood stem cell transplantation (PBSCT) from matched siblings has lead to clinical results comparable to those of standard bone marrow transplantation (BMT). We report the outcome of 79 patients transplanted with PBSC from unrelated donors. DESIGN AND METHODS: In 61 cases PBSC were used for primary transplantation whereas 18 patients were treated for relapse or graft-failure. In 35 patients receiving primary transplants, T-cell depletion (TCD) using CD34 positive selection of PBSC with or without additional T-cell depletion had been performed to reduce the risk of graft-versus-host-disease (GvHD). RESULTS: The rate of primary graft-failure was higher (20%) in the TCD group than in that receiving unmanipulated grafts (UM) (5%, p=0.007). Patients with standard risk (n=34) receiving first transplants had a significantly better overall (60.4% vs. 24%, p=0.02) and disease-free survival (57.2% vs. 22.3%, p=0.006) compared to a high risk group of patients (n=21). There were no differences in the speed of neutrophil and platelet engraftment between TCD and UM transplants. As expected, the cumulative risk for acute GvHD grade II.-IV was significantly higher in the patients who had received UM grafts (71.8% vs. 38.1%, p=0.005). Although a trend towards a better survival rate was observed after TCD transplantation (52.2%) compared to the UM group (38.1%), this difference was not statistically significant. The probability of relapse was significantly higher in patients after UM transplants (38.8% vs. 8. 4%). This apparent paradox is explained by the higher number of high-risk patients in this group (p=0.03). Multivariable analysis of disease-free survival revealed risk category (p=0.02) and use of ATG (p=0.03) to be of significant impact. All patients (n=6) with non-malignant diseases are alive with full donor chimerism. INTERPRETATION AND CONCLUSIONS: These data show that PBSC from unrelated donors can be transplanted either unmanipulated or CD34 selected. Prospective studies comparing BMT with PBSCT from unrelated donors are needed in defined disease categories.
Assuntos
Fator Estimulador de Colônias de Granulócitos/farmacologia , Mobilização de Células-Tronco Hematopoéticas , Transplante de Células-Tronco Hematopoéticas/métodos , Doadores de Tecidos , Transplante Homólogo/métodos , Adolescente , Adulto , Causas de Morte , Criança , Pré-Escolar , Intervalo Livre de Doença , Feminino , Doenças Genéticas Inatas/mortalidade , Doenças Genéticas Inatas/terapia , Alemanha/epidemiologia , Rejeição de Enxerto , Sobrevivência de Enxerto , Doença Enxerto-Hospedeiro/epidemiologia , Doença Enxerto-Hospedeiro/etiologia , Doenças Hematológicas/mortalidade , Doenças Hematológicas/terapia , Neoplasias Hematológicas/mortalidade , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas/estatística & dados numéricos , Humanos , Terapia de Imunossupressão/métodos , Lactente , Infecções/etiologia , Infecções/mortalidade , Tábuas de Vida , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Risco , Condicionamento Pré-Transplante , Transplante Homólogo/estatística & dados numéricos , Resultado do TratamentoRESUMO
BACKGROUND: Recombinant human G-CSF is widely used to mobilize PBPCs in healthy donors for allogeneic transplantation. There have been concerns about donor safety because of splenic ruptures during G-CSF application. To address this problem, changes in splenic size in 91 healthy donors during G-CSF mobilization of allogeneic PBPCs were investigated. STUDY DESIGN AND METHODS: For mobilization, G-CSF in a dosage of 7.5 microg per kg per day was administered for 5 days and PBPC collection started Day 5. Splenic size was determined by ultrasound before G-CSF application was started and on the day of the first apheresis. RESULTS: The mean increase in splenic length was 11 mm (range, 0-28 mm; p<0.0001), whereas a mean increase of 5 mm in width (range, 0-14 mm; p<0.0001) was measured. No major side effects could be observed. There was no significant correlation between the increase in splenic size and the hematologic values, or the age and body-mass index. In a multivariant analysis, no independent risk factor for the development of a spleen enlargement over 19 mm in length and 9 mm in thickness was found in 20 percent of investigated donors. CONCLUSION: In this prospective trial, a significant spleen enlargement was observed in healthy donors during G-CSF mobilization of allogeneic PBPCs. Further investigations are needed to define the degree of spleen enlargement with higher G-CSF dosages to improve donor safety.
Assuntos
Doadores de Sangue , Fator Estimulador de Colônias de Granulócitos/farmacologia , Mobilização de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/metabolismo , Esplenomegalia/sangue , Células-Tronco Hematopoéticas/efeitos dos fármacos , Humanos , Estudos Prospectivos , Baço/efeitos dos fármacosRESUMO
Peripheral blood stem cell (PBSC) transplants from HLA-A, -B, and -DR compatible unrelated donors (n = 45) were compared with bone marrow (BM; BM group, n = 45). Eighteen patients received CD34-selected PBSC (CD34 group). The PBSCs contained more mononuclear cells, CD34(+), CD3(+), and CD56(+) cells compared with marrow (P <.001). Engraftment was achieved in all 45 patients in the BM group, in 43 of 45 (95%) in the PBSC group, and in 14 of 18 (78%) in the CD34 group (P <.01). In multivariate analysis, a short time to absolute neutrophil count (ANC) equal to 0.5 x 10(9)/L was associated with the PBSC/CD34 groups (P <.001) and granulocyte colony-stimulating factor (G-CSF) treatment (P =.017). A short time to platelets equal to 50 x 10(9)/L was associated with PBSC (P =. 003) and no methotrexate (P =.015). Grades II-IV acute graft-versus-host disease (GVHD) was 20% in the BM controls, 30% in the PBSC group, and 18% in the CD34 group (not significant [NS]). The probability of chronic GVHD was 85% in the BM group, 59% in the PBSC group, and 0% in the CD34 group (P <.01). One-year transplant-related mortality was 21% and 27% and survival was 53% and 54% in the BM and PBSC groups, respectively (NS). The 2-year relapse-free survival was 41% and 46% in the two groups, respectively.